Navigation Links
MannKind to Present at the Rodman & Renshaw Annual Global Investment Conference
Date:11/3/2008

VALENCIA, Calif., Nov. 3 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Rodman & Renshaw Annual Global Investment Conference on Monday, November 10, 2008 at 9:55 AM (EST) at the New York Palace Hotel in New York City.

Interested parties can access a link to the live web cast of the presentation in the Investor Relations section of the Company's website at http://www.mannkindcorp.com. A replay of the presentation will be available for 14 days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFRESA(TM), which has completed Phase 3 clinical trials, and MKC253, which is currently in phase 1 clinical trials. Both of these investigational products are being evaluated for their safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit http://www.mannkindcorp.com.


'/>"/>
SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. MannKind to Present at the UBS Global Life Sciences Conference
2. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
3. MannKind Announces Positive Results from a Phase 1a Study of a GLP-1 Formulation
4. MannKind to Present at the Piper Jaffray Healthcare Conference
5. MannKind to Present at the Wachovia 2008 Healthcare Conference
6. MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
7. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008
8. MannKind Corporation Response to Recent Market Events
9. Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer
10. MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 5, 2008
11. MannKind to Present at the Morgan Stanley Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 Polaris Group announced today that ... Phase 1 trial of ADI-PEG 20 in combination ... malignant pleural mesothelioma (MPM) and non-squamous non-small cell ... on ADI-PEG 20, both as monotherapy and in ... several other indications, including breast cancer, melanomas, ovarian ...
(Date:11/18/2014)... Calif. , Nov. 18, 2014 Cord ... platinum sponsor of the 10th Annual World Stem Cell Summit, ... medicine stakeholders. The 2014 World Stem Cell Summit will be ... San Antonio, Texas . The ... and development of lifesaving cures and therapies, convening the most ...
(Date:11/18/2014)... 17, 2014 Athena Signature Series: Turning Cancer ... Beverly Emerson, a professor in the Regulatory Biology Laboratory at ... recent discovery points to an “off switch” for drug resistance ... how her local research is making a global impact in ... and then join host Cheryl K. Goodman, CEO of Social ...
(Date:11/18/2014)... (PRWEB) November 18, 2014 ... (PTMEG) Industry is professional and in-depth report ... Polytetrahydrofuran basic information, including its definition, characterization, ... industry outline. This exploration covers the worldwide ... worldwide industry examination covering macroeconomic environment & ...
Breaking Biology Technology:Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 2PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 3
... 27 Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), ... Jerry McMahon, Ph.D., chairman and CEO,will participate in ... provide a corporate overview, including a discussion of ... product candidate., -- The Thomas Weisel Partners ...
... Buckler appointed to Regenerative Medicine editorial board. , ... ... ( www.celltherapygroup.com ) announced today the appointment of its principle consultant, ... Medicine. , , , , ,Published by Future Medicine, Regenerative ...
... INVESTMENT BANKING FIRM HAS STRONG BACKGROUND IN BIOTECHNOLOGY, ... or "the Company") (OTC Bulletin Board: SOBM) is ... Partners, Inc. as its financial,advisor to evaluate strategic ... are extremely pleased with the results obtained from ...
Cached Biology Technology:Poniard Pharmaceuticals Announces Upcoming Conference Participation 2Regenerative Medicine Appoints Cell Therapy Group Consultant to Editorial Board 2Sinobiomed Retains CB Capital Partners as Financial Advisor to Maximize Shareholder Value 2Sinobiomed Retains CB Capital Partners as Financial Advisor to Maximize Shareholder Value 3
(Date:11/7/2014)... SPRINGS, Florida , November 6, 2014 ... secure authentication for better mobile security revolutionizing online transactions.  Companies ... ), Alibaba Holdings Ltd. (NYSE: BABA ), Google ... MSFT ), eBay Inc. (NASDAQ: EBAY ) ... NXTD and NXTDW), a biometric authentication company ...
(Date:11/6/2014)... deaths occur because of metastasis, yet progress in ... slow. , "It,s been particularly challenging to design ... research fellow in systems biology at Harvard Medical ... until after they,ve already metastasized." , Gujral and ... should help researchers better understand how metastasis begins. ...
(Date:11/6/2014)... Baltimore, MD, November 6, 2014 - Insilico Medicine, ... in aging and age related diseases announced a ... medicine of cancer, Champions Oncology, Inc (OTC: CSBR). ... genomics for personalized medicine, but Champions Oncology,s TumorGraft ... can validate the chemotherapy regimen experimentally generating vast ...
Breaking Biology News(10 mins):Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6Migration negation 2Migration negation 3Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... 14 issue of the journal Science shows, for the first ... are driving nearby populations of wild salmon toward extinction. The ... rapidly declining for four years. The scientists expect a 99% ... the infestations continue. The impact is so severe that ...
... THE SITUATION: The largest living structures on ... are at risk, the most definitive review yet of the ... In a paper published in the prestigious Science Magazine ... a race against time in preparing coral reefs and the ...
... Lab, in collaboration with the Institutes Imaging Center, ... the dynamic protein-protein interactions in the mitogen-activated protein ... to growth and differentiation decisions in all eukaryotic ... in the MAP Kinase Signaling Using Live-Cell Fluorescence ...
Cached Biology News:Fish farms drive wild salmon populations toward extinction 2Fish farms drive wild salmon populations toward extinction 3Fish farms drive wild salmon populations toward extinction 4It's official: The carbon crisis is lethal for coral reefs 2It's official: The carbon crisis is lethal for coral reefs 3It's official: The carbon crisis is lethal for coral reefs 4Rong Li Lab reports protein interactions of MAP kinase signaling pathway 2
Affinity Purified Rabbit Anti-mouse sRANKL Biotinylated Polyclonal Antibody...
Rabbit polyclonal to FOXJ2 ( Abpromise for all tested applications). entrezGeneID: 55810 SwissProtID: Q9P0K8...
Selenoprotein P Purified Anti-Mouse clone 35, Isotype Mouse IgG 2b , 50 µg Consult technical datasheet for details....
Mouse monoclonal [3B6] to HSV1 + HSV2 ICP5 Major Capsid Protein ( Abpromise for all tested applications)....
Biology Products: